Find uplifting stories about heroes, innovations, and solutions
15 results for "retatrutide"
Scientists are testing a breakthrough obesity treatment that helps people lose up to a third of their body weight without sacrificing muscle mass. The triple-action drug retatrutide could solve one of the biggest problems with current weight-loss medications.
A promising triple-action medication could help people lose weight without sacrificing muscle. Retatrutide shows potential for safer weight loss with fewer side effects than earlier medications.
A breakthrough medication called retatrutide helped people with type 2 diabetes lose an average of nearly 37 pounds while controlling their blood sugar in just 40 weeks. The drug represents a new era in treating diabetes and obesity, giving doctors more tools to help patients live healthier lives.
A groundbreaking triple-action weekly injection helped people with type 2 diabetes lose more than four times the weight of standard treatment while dramatically improving blood sugar control. The drug works differently than existing medications by targeting three hormones instead of one or two.
A groundbreaking medication helped people lose an average of 70 pounds while simultaneously improving diabetes, sleep apnea, and arthritis pain. The triple-action drug could transform how doctors treat obesity and its related health problems.
A groundbreaking obesity medication helped people lose an average of 70 pounds in clinical trials, matching results previously only seen with bariatric surgery. The drug offers new hope for millions struggling with obesity and related health conditions.
Eli Lilly's experimental obesity medication helped patients lose an average of 28% of their body weight in a major trial, matching results typically seen only with bariatric surgery. The breakthrough treatment offers new hope for millions struggling with obesity, though researchers are working to reduce side effects.
Eli Lilly has granted one person extraordinary access to its next-generation obesity treatment through an FDA compassionate use program. The decision marks a rare exception that could offer hope to patients waiting for breakthrough treatments.
A new diabetes treatment from Eli Lilly helped patients lose 15% of their body weight while improving blood sugar control, potentially becoming the most effective weight loss diabetes drug yet. The results offer hope for millions who struggle to shed pounds while managing their condition.
A groundbreaking medication just moved closer to FDA approval after helping trial participants lose an average of 70 pounds in 80 weeks. The drug matches results typically seen only with surgery, offering new hope for millions struggling with obesity.
Eli Lilly is building a $3.5 billion manufacturing facility in Pennsylvania to produce breakthrough obesity treatments, including an experimental drug showing record-breaking weight loss results. The plant will create 850 permanent jobs and 2,000 construction positions when it opens in 2031.
A breakthrough obesity treatment helped patients lose nearly 30% of their body weight—results previously only achievable through surgery. The experimental drug could transform how millions manage obesity while Medicare makes these treatments more affordable.
Eli Lilly's new obesity medication helped people with diabetes achieve significant weight loss and better blood sugar control, a notoriously difficult combination to achieve. While researchers are monitoring some cardiac events, the drug represents a major step forward for millions struggling with both conditions.
Pharmaceutical giant Eli Lilly achieved positive results in nearly all its 2025 clinical trials, bringing new treatments for obesity, diabetes, and cancer closer to patients who need them. The company is also building the world's largest pharmaceutical AI supercomputer to speed up future drug discoveries.
After decades of research, personalized medicine has arrived with treatments that once seemed impossible. New diabetes drugs, RSV vaccines, and cancer screening advances are transforming patient care right now.